EU Stands Firm Against Big Pharma's Lobbying Efforts

The European Union has confirmed a new measure that will remove two years of data protection from all new medicines launched in the EU, allowing unbranded rivals to enter the market more quickly. The reform aims to tackle the uneven rollout of drugs across the EU and includes incentives for pharmaceutical companies that launch their medicines in all EU 27 countries. The regulation and directive will have to go through the EU's legislative process before being approved, and it's unlikely this will be done before European Parliament elections in 2024.